Tarsus Pharmaceuticals, Inc.
TARS
$40.81
$1.995.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.12M | -23.11M | -23.42M | -33.29M | -35.73M |
| Total Depreciation and Amortization | 460.00K | 432.00K | 284.00K | 239.00K | 270.00K |
| Total Amortization of Deferred Charges | 139.00K | 138.00K | 129.00K | 101.00K | 114.00K |
| Total Other Non-Cash Items | 5.78M | 6.09M | 6.45M | 8.29M | 6.15M |
| Change in Net Operating Assets | -1.91M | -5.73M | 7.91M | 10.25M | -8.59M |
| Cash from Operations | -20.65M | -22.18M | -8.65M | -14.40M | -37.79M |
| Capital Expenditure | -590.00K | -72.00K | -282.00K | -1.04M | -174.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -34.35M | -59.50M | 3.41M | -39.49M | -102.05M |
| Cash from Investing | -34.94M | -59.57M | 3.13M | -40.53M | -102.22M |
| Total Debt Issued | -- | 0.00 | 0.00 | 75.00M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 136.56M | 2.93M | 678.00K | -- | 99.41M |
| Repurchase of Common Stock | -- | -- | -- | -6.69M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -39.00K | -26.00M | 9.37M |
| Cash from Financing | 136.56M | 2.93M | 639.00K | 42.32M | 108.77M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.97M | -78.83M | -4.89M | -12.61M | -31.24M |